[1]郑家平,邵国良,罗 君,等. 索拉非尼治疗中晚期肝细胞癌安全性和预后因素分析[J].介入放射学杂志,2014,(03):222-225.
　ZHENG Jia? ping,SHAO Guo? liang,LUO Jun,et al. Sorafenib for the treatment of intermediate?蛳 advanced hepatocellular carcinomas： its safety and prognostic factors[J].journal interventional radiology,2014,(03):222-225.
点击复制

 索拉非尼治疗中晚期肝细胞癌安全性和预后因素分析 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2014年03期
页码:
222-225
栏目:
肿瘤介入
出版日期:
2014-03-25

文章信息/Info

Title:
 Sorafenib for the treatment of intermediate?蛳 advanced hepatocellular carcinomas： its safety and prognostic factors
作者:
 郑家平;  邵国良;  罗 君;  陈玉堂;  姚 征;  曾 晖;  郝伟远

Author(s):
 ZHENG Jia?蛳 ping;  SHAO Guo?蛳 liang;  LUO Jun;  CHEN Yu?蛳 tang;  YAO Zheng;  ZENG Hui;  HAO Wei?蛳 yuan.
 Department of Interventional Radiology， Zhejiang Provincial Cancer Hospital， Hangzhou， Zhejiang Province 310022， China
关键词:
【关键词】 癌; 肝细胞;  索拉非尼;  治疗
文献标志码:
A
摘要:
 【摘要】 目的 探讨索拉非尼治疗中晚期肝细胞癌（HCC）的安全性及影响预后的因素。方法 2006年2月—2012年12月，89例中晚期HCC患者接受索拉非尼靶向治疗。采用单因素和多因素分析患者各项临床病理学参数与其预后的关系，并观察索拉非尼相关不良反应。结果 74例患者可作疗效评价，死亡45例，存活27例，失访2例。疾病控制率（DCR）85.14%。中位肿瘤进展时间（mTTP）6.53个月（95%CI：4.79 ~ 8.26个月），中位总生存时间（mOS）9.93个月（95%CI：8.13 ~ 11.74个月）。单因素分析发现，PS评分、Child?蛳 Pugh分级、BCLC分期、肿瘤血管侵犯及不同的治疗模式对预后的影响有统计学意义。进一步多因素分析发现，Child?蛳 Pugh分级和治疗模式是患者预后的独立影响因素（P < 0.05）。服用索拉非尼主要不良反应为手足皮肤反应、消化道不良反应、乏力、骨髓抑制等。结论 肝功能良好的HCC患者采用TACE术后序贯索拉非尼治疗可获得较长的生存时间和疾病稳定状态。口服索拉非尼不良反应大多可以耐受。

参考文献/References:

 ［1］ Cheng AL， Kang YK， Chen Z， et al. Efficacy and safety of sorafenib in patients in the Asia?蛳 Pacific region with advanced hepatocellular carcinoma： a phase Ⅲ randomised， double?蛳 blind， placebo?蛳 controlled trial［J］. Lancet Oncol， 2009， 10： 25 ?蛳 34.
［2］ Lovet JM， Ricci S， Mazzaferro V， et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med， 2008， 359： 378 ?蛳 390.
［3］ Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma［J］. Cancer， 2008， 112： 250 ?蛳 259.
［4］ Cheng AL， Guan Z， Chen Z， et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status： subset analyses of the phase Ⅲ Sorafenib Asia?蛳 Pacific trial［J］. Eur J Cancer， 2012， 48： 1452 ?蛳 1465.
［5］ 中华人民共和国卫生部． 原发性肝癌诊疗规范（2011年版）［J］． 临床肿瘤学杂志， 2011， 16： 929 ?蛳 946．
［6］ Llovet JM， Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma： Chemoembolization improves survival［J］. Hepatology， 2003， 37： 429 ?蛳 442.
［7］ Eisenhauer EA， Therasse P， Bogaerts J， et al. New response evaluation criteria in solid tumours： revised RECIST guideline （version 1.1）［J］. Eur J Cancer， 2009， 45： 228 ?蛳 247.
［8］ Sergio A， Cristofori C， Cardin R， et al. Transcatheter arterial chemoembolization （TACE） in hepatocellular carcinoma （HCC）： the role of angiogenesis and invasiveness［J］. Am J Gastroenterol， 2008， 103： 914 ?蛳 921.
［9］ 魏照光， 陆骊工， 邵培坚， 等． 肝动脉化疗栓塞联合索拉非尼治疗中晚期肝细胞癌的临床疗效观察［J］． 中华放射学杂志， 2012， 46： 252 ?蛳 256．
［10］ Sansonno D， Lauletta G， Russi S， et al. Transarterial chemoembolization plus sorafenib： a sequential therapeutic scheme for HCV?蛳 related intermediate?蛳 stage hepatocellular carcinoma： a randomized clinical trial［J］. Oncologist， 2012， 17： 359 ?蛳 366.
［11］ Iavarone M， Cabibbo G， Piscaglia F， et al. Field?蛳 practice study of sorafenib therapy for hepatocellular carcinoma： a prospective multicenter study in Italy［J］. Hepatology， 2011， 54： 2055 ?蛳 2063.
［12］ Tsukui Y， Mochizuki H， Hoshino Y， et al. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib［J］. Hepatogastroenterology， 2012， 59： 2536 ?蛳 2539.
［13］ Pinter M， Sieghart W， Hucke F， et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib［J］. Aliment Pharmacol Ther， 2011， 34： 949 ?蛳 959.
［14］ Sieghart W， Pinter M， Reisegger M， et al. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma： a pilot study［J］. Eur Radiol， 2012， 22： 1214 ?蛳 1223.
［15］ Kudo M， Imanaka K， Chida N， et al. Phase Ⅲ study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma［J］. Eur J Cancer， 2011， 47： 2117 ?蛳 2127.

相似文献/References:

[1]申淑群,杨业发,葛乃建,等.肝癌破裂出血的介入与外科手术疗效评价[J].介入放射学杂志,2010,(07):544.
　SHEN Shuqun,YANG Yefa,GE Naijian,et al.Evaluation of interventional and surgical treatments for the hemorrhage of ruptured hepatocellular carcinoma[J].journal interventional radiology,2010,(03):544.
[2]郑加生,崔雄伟,禹纪红.自发性肝癌破裂出血的急诊动脉栓塞治疗[J].介入放射学杂志,2006,(04):228.
　ZHANG Jia-sheng,CUI Xiong-wei,YU Ji-hong,et al.Emergency transcatheter arterial embolization for beeding of hepatocellular carcinoma spontaneous rupture[J].journal interventional radiology,2006,(03):228.
[3]李强,曾从俊,王莺.化疗栓塞联合质子放射治疗肝癌合并门脉主干癌栓的临床应用[J].介入放射学杂志,2009,(04):278.
　LI Qiang,ZENG Congjun,WANG Ying.Interventional chemoembolization combined with proton radiotherapy for the treatment of hepatocellular carcinoma accompanied with portal cancerous thrombus[J].journal interventional radiology,2009,(03):278.
[4]张长青,吴伟岗,曾志雄,等.肝动脉化疗栓塞及注射~(32)P-胶体、无水乙醇综合序贯介入治疗原发性肝癌疗效分析[J].介入放射学杂志,2000,(01):22.
[5]经 翔,丁建民,王彦冬,等. 射频消融和微波消融治疗肝癌的比较[J].介入放射学杂志,2014,(04):306.
　JING Xiang,DING Jian? min,WANG Yan? dong,et al. Ultrasound-guided percutaneous radiofrequency ablation and microwave ablation for the treatment of hepatocellular carcinoma： a comparison study[J].journal interventional radiology,2014,(03):306.
[6]钱 晟,刘 嵘,王建华,等.栓塞肝动脉-门静脉瘘在TACE联合门静脉支架治疗肝癌伴门静脉癌栓中的临床意义[J].介入放射学杂志,2015,(04):306.
　QIAN Sheng,LIU Rong,WANG Jian hua,et al.Embolization of hepatic arterio portal shunt in patients with HCC complicated by portal vein tumor thrombus treated with TACE combined with portal vein stenting： its clinical significance[J].journal interventional radiology,2015,(03):306.
[7]刘秋松,梅雀林,李彦豪,等.化疗栓塞治疗肝癌合并肝动-静脉分流的生存预后因素分析[J].介入放射学杂志,2015,(12):1056.
　LIU Qiu-song,MEI Que-lin,LI Yan-hao,et al.Interventional chemoembolization for the treatment of hepatocellular carcinoma associated with hepatic arteriovenous shunt： analysis of survival prognostic factors[J].journal interventional radiology,2015,(03):1056.
[8]刘秋松,梅雀林,何晓峰,等.索拉非尼联合PVA微粒化疗栓塞治疗肝癌并肝动-静脉分流的疗效及预后分析[J].介入放射学杂志,2016,(04):320.
　LIU Qiu- song,MEI Que- lin,HE Xiao- feng,et al.Sorafenib plus percutaneous chemoembolization with polyvinyl alcohol for hepatocellular carcinoma complicated by hepatic arteriovenous shunts： analysis of curative effect and prognosis[J].journal interventional radiology,2016,(03):320.
[9]黄 芳,龚环宇,熊正平.雷替曲塞联合奥沙利铂TACE治疗BCLC B/C期肝细胞癌的安全性及疗效[J].介入放射学杂志,2018,27(01):76.
　HUANG Fang,GONG Huanyu,XIONG Zhengping.The safety and efficacy of raltitrexed combined with oxaliplatin in TACE treatment for BCLC B/C hepatocellular carcinomas[J].journal interventional radiology,2018,27(03):76.
[10]戴高乐,罗万权,赵许亚,等.眼部Merkel细胞癌介入治疗1例[J].介入放射学杂志,2020,29(10):1060.
　DAI Gaole,LUO Wanquan,ZHAO Xuya,et al.Successful interventional treatment of Merkel cell carcinoma located at the lateral canthus of left eye： report of one case[J].journal interventional radiology,2020,29(03):1060.
[11]周卫忠,刘 圣,杨正强,等.氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析[J].介入放射学杂志,2013,(08):641.
　ZHOU Wei? zhong,LIU Sheng,YANG Zheng? qiang,et al. Transarterial embolization therapy with cyanoacrylate for severe arterioportal shunt associated with hepatocellular carcinoma[J].journal interventional radiology,2013,(03):641.
[12]万豪光,许 伟,徐 浩,等. 经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析[J].介入放射学杂志,2014,(06):477.
　WAN Hao- guang,XU Wei,XU Hao,et al. Transcatheter arterial chemoembolization combined with percutaneous microwave ablation for the treatment of intermediate- advanced hepatocellular carcinoma： analysis of prognostic factors in 64 cases[J].journal interventional radiology,2014,(03):477.
[13]涂文辉,罗剑钧,刘清欣,等.原发性肝癌伴门静脉主干癌栓患者存活超5年1例并文献复习[J].介入放射学杂志,2015,(12):1101.
　TU Wen- hui,LUO Jian- jun,LIU Qing- xin,et al.Primary hepatocellular carcinoma associated with portal vein tumor thrombus： report of one case with survival over 5 years and review of literature [J].journal interventional radiology,2015,(03):1101.
[14]孙 玉,张洪海,生守鹏,等.白蛋白-胆红素分级在早期肝细胞癌射频消融中的预后意义 [J].介入放射学杂志,2021,30(05):502.
　SUN Yu,ZHANG Honghai,SHENG Shoupeng,et al.Prognostic significance of albumin-bilirubin grading in patients with early hepatocellular carcinoma after radiofrequency ablation treatment[J].journal interventional radiology,2021,30(03):502.
[15]李 卿,梁 斌.化疗栓塞联合替拉扎明治疗肝癌的研究进展[J].介入放射学杂志,2021,30(08):846.
　LI Qing,LIANG Bin..Research progress in the treatment of hepatocellular carcinoma with chemoembolization combined with tirapazamine[J].journal interventional radiology,2021,30(03):846.
[16]中国医师协会介入医师分会临床诊疗指南专委会.肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J].介入放射学杂志,2022,31(11):1039.
　Expert consensus on the TACE failure/refractoriness and its subsequent therapies in treating patients with hepatocellular carcinoma Clinical Guidelines Committee of Chinese College of Interventionalists[J].journal interventional radiology,2022,31(03):1039.

备注/Memo

备注/Memo:
 （收稿日期：２０１3-０5-０8）
更新日期/Last Update: